That's a great point lorbas. So, within the Prima
Post# of 145782
Do the four measurements provide more statistical strength? Or does the relatively small size create a situation where the p value could be high without a dramatic improvement from the leronlimab group?
And, further if we do in fact achieve p< .05 I would imagine its at the discretion of FDA whether to request a PH3. And would this be determined by the strength of the p value?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)